The use of integrated text mining and protein-protein interaction approach to evaluate the effects of combined chemotherapeutic and chemopreventive agents in cancer therapy

Mohammad Rasoul Samandari Bahraseman¹,²*, Babak Khorsand³*, Keyvan Esmaeilzadeh-Salestani⁴, Solmaz Sarhadi², Nima Hatami⁵, Banafsheh Khaleghdoust⁴, Evelin Loit¹

¹ Faculty of Sciences, Department of Biology, Shahid Bahonar University of Kerman, Kerman, Iran, ² Varjavand Kesht Kariman, Limited Liability Company, Kerman, Iran, ³ Computer Engineering Department, Ferdowsi University of Mashhad, Mashhad, Iran, ⁴ Chair of Crop Science and Plant Biology, Institute of Agricultural and Environmental Sciences, Estonian University of Life Sciences, Kreutzwaldi, Tartu, Estonia, ⁵ Kerman Department of Endodontic Dentistry, Kerman University of Medical Sciences, Kerman, Iran

* m.r.samandari@gmail.com (MRSB); khorsand@mail.um.ac.ir (BK)

Abstract

Combining chemotherapeutic (CT) and chemopreventive (CP) agents for cancer treatment is controversial, and the issue has not yet been conclusively resolved. In this study, by integrating text mining and protein-protein interaction (PPI), the combined effects of these two kinds of agents in cancer treatment were investigated. First, text mining was performed by the Pathway Studio database to study the effects of various agents (CP and CT) on cancer-related processes. Then, each group’s most important hub genes were obtained by calculating different centralities. Finally, the results of in silico analysis were validated by examining the combined effects of hesperetin (Hst) and vincristine (VCR) on MCF-7 cells. In general, the results of the in silico analysis revealed that the combination of these two kinds of agents could be useful for treating cancer. However, the PPI analysis revealed that there were a few important proteins that could be targeted for intelligent therapy while giving treatment with these agents. In vitro experiments confirmed the results of the in silico analysis. Also, Hst and VCR had good harmony in modulating the hub genes obtained from the in silico analysis and inducing apoptosis in the MCF-7 cell line.

Introduction

Cancer is one of the leading causes of death in the world. If cells damaged by mutations cannot repair themselves and inhibit cell growth during the tumorigenic process, they will become cancer cells [1]. The most common treatments against cancer include chemotherapy, surgery, and radiation therapy, each of which has its own disadvantages [2]. For example, chemotherapy as a conventional method leads to unwanted side effects and drug resistance [3,4]. Therefore, finding new therapeutic strategies is one of the most important concerns of researchers who are trying to improve the cancer treatment processes.
The term chemoprevention, which refers to inhibiting, suppressing, or reversing cancer progression by using natural or synthetic compounds, was first coined by Sporn in the early 1970s [5]. Introducing an agent as a chemopreventive (CP) agent, with no side effects is one of the prerequisites [6]. In addition to their preventive properties, CP agents are effective in inhibiting cell proliferation and inducing apoptosis in human cancer cells [7]; thus, it can be concluded that these agents can play important therapeutic roles in cancer treatment.

One of the most essential strategies for improving the effectiveness of different drugs used for cancer treatment is combination therapy. The synergistic effect could increase the performance of various anti-cancer drugs [8–11]. Numerous investigations have indicated that CP agents, in combination with CT, can induce an additive or synergistic effect in stimulating cell death. Nevertheless, the application of these agents for cancer therapy or in combination therapy with CT agents to improve treatment efficiency is controversial and has not reached a definitive conclusion due to insufficient information [12,13]. For example, some clinical studies have reported that the application of CP agents in combination with CT agents was ineffective for cancer therapy and can lead to an increased risk of death in some cases [14,15]. Therefore, scrutinizing the combined effects of these factors in cancer therapy is crucial.

Vincristine (VCR) is a natural vinca alkaloid derived from the plant Catharanthus roseus and is widely used as a CT agent in treating various cancers [16,17]. Although VCR has a long history of being used in the fight against cancer, its dose-dependent side effects cause neurotoxicity [18,19]. Hesperetin (Hst) is a flavonoid subgroup found naturally in citrus fruits [20]. Numerous preclinical studies have shown that Hst has a protective role against cancer’s malignant progression through various cellular signaling pathways [21,22]. So far, no studies have been conducted on the combined effects of these two factors on cancer.

Pathway Studio is a comprehensive database of full-text articles, abstracts, and clinical trial information, covering more than 10,000 journals and giving users access to the largest biomedical database and related content. By providing statistical tools, this database allows researchers to extract and analyze their experimental and applied information [23].

Since we aimed at investigating whether CP agents could be effective in adjunctive therapy in cancer treatment when used along with CT agents, five CP agents were selected so their effects could be evaluated when used in combination with two CT agents. This study presents a pipeline in which, by evaluating the effects of these agents on the proteins involved in cancer-related signaling pathways, the negative or positive effects of these two types of agents on cancer treatment could be determined. The effect of the combination of VCR and Hst was measured against MCF-7 cancer cells to validate the in silico results. Researchers can use this method in the future to investigate the combined effect of various drugs on diseases.

Materials and methods

Text-mining analysis

The effects of CP and CT agents on cellular signaling pathways related to cancer were evaluated using the Pathway Studio Mammal Plus database [23]. Five CP (curcumin, resveratrol, quercetin, silibinin, and Hst) and two CT agents (doxorubicin and VCR) were selected as an input, and various cancer-related cellular signaling processes were selected as the targets to be analyzed by the Pathway Studio Mammal Plus software in 2020 (www.pathwaystudio.com). The pathway-studio output contains information about the impact of each input on the target as a “positive effect,” “negative effect,” or “both positive and negative effects.” First, the obtained information was carefully reviewed to evaluate the accuracy of the mined text. Although the results of the Pathway Studio were sometimes not correct, overall, they were accurate in over 95 percent of the cases. Then, the results were categorized into four "positive," "negative,"
"unknown," and “dual-role” groups. The logic behind this classification was based on the effects of each agent on the cancer treatment process. For example, where the effects of the agents on the P53 were positive in the Pathway Studio results, it was considered a positive effect in the treatment of cancer. The results of most findings in the various literature were considered a decision criterion to determine genes that have a dual role (positive and negative) in the treatment processes. For example, genes such as NF-κB are involved in different processes, and many studies have reported that increased expression of this gene causes resistance to cancer treatment, but some studies have also shown the effectiveness of this gene in inducing apoptosis. Moreover, the increase of intracellular ROS was considered a stimulus for cell death, so the effect of genes related to this process was classified accordingly (S1 Data).

**Enrichment and network analysis**

The text-mining results were divided into four groups based on their effects on cancer treatment for network analysis. Group 1: The effects of both CT and CP agents on cancer treatment were positive. Group 2: The effects of CP agents on the treatment process were positive, and the effects of CT agents were negative. Group 3: The effects of CT agents were positive, and the effects of CP agents were negative. Group 4: The effects of both CT and CP agents were negative.

Human protein-protein interaction network (HPPIN) is a graph in which the nodes are human proteins (HPs), and the edges show the interaction between them (S1 Fig). The HPPIN has 288989 experimental interactions between 20748 HPs [24]. Different centralities are used to score each HP [25].

Degree (connectivity): Degree centrality of per HP \( (D_i \text{ for } HP_i) \) is the digit of its neighbors in HPPIN.

Neighborhood connectivity: Neighborhood connectivity per HP \( (N_i \text{ for } HP_i) \) is the average degree of its neighbors which is described as \( Eq 1 \).

\[
N_i = \sum_{j: D_j} D_j
\]  

\( Eq 1 \)

Shortest paths: The shortest path centrality \( (S_i \text{ for } HP_i) \), as it is illustrated in \( Eq 2 \), is the synopsis of the shortest path between that HP and all the other HPs divided by the entire number of HPs \( (n) \). The shortest path between nodes \( i \) and \( j \) \( (S_{i,j}) \) is the number of edges that should be traversed to reach \( j \) from \( i \).

\[
S_{i,j} = (\sum_{j=1}^{n} S_{i,j})/n
\]  

\( Eq 2 \)

Betweenness centrality: The betweenness centrality of each HP is characterized as the ratio of the shortest paths that pass via that HP which is represented as \( Eq 3 \). \( \sigma_{j,k} \) and it is the number of the shortest path between \( j \) and \( k \), while \( \sigma_{j,k}(i) \) is the number of the shortest paths between \( j \) and \( k \) which pass through \( i \).

\[
B_i = \sum_{j=1}^{n-1} \sum_{k=1}^{n} \frac{\sigma_{j,k}(i)}{\sigma_{j,k}}
\]  

\( Eq 3 \)

Closeness centrality: The closeness centrality of an HP represents the joint of its average shortest path distance in the whole HPPIN.

Diversity of Predators: In the Human-Virus PPI network, for each HP, each of the virus families that interact with it is called a predator. For each HP, the mean evolutionary length of its predators multiplied by the number of its predators is regarded as its diversity of predators (DP) score [26].
The igraph package calculated the centrality measures in the R programming language. All these centralities were calculated in each group, and the genes with the highest scores were selected as hub genes. For groups 1 and 2, which had the largest number of genes, the evaluation was done on the top 10 centralities, while for the next groups, which had fewer genes, the top 5 centralities were evaluated. Finally, enrichment analysis was performed by the DAVID database to investigate the effects of these hub genes on the biological processes.

Cell culture
MCF-7 cells (human breast adenocarcinoma cell line) were purchased from the Iranian Genetic Resources Center. The MCF-7 cells were grown in DMEM medium with 10% fetal bovine serum and the antibiotics penicillin (100 U/ml) and streptomycin (100 g/ml). The cells were cultured at a density of 5000 cells per well in a 96-well plate for MTT testing. For western blotting and real-time PCR, MCF-7 cells were grown in a 6-well plate and allowed to bind and grow for 24 h for the protein and RNA to be extracted. Then, the cells were treated with VCR, Hst, and the combined dose and were also incubated for 24 h.

Cell viability analysis
Cell viability was evaluated using the MTT assay, which is based on the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by a mitochondrial dehydrogenase into an aqueous formulation product. The MTT powder was dissolved in PBS with a final concentration of 0.5 μg/ml. After treatment of the cells in the 96-well plate, they were incubated for 24 h. Then, 30 μL of dissolved MTT was added to each well, and the wells were kept in an incubator for 3 h. After removal of the medium culture, 100 μL of DMSO was added to each well to dissolve the formed formazan crystals. Finally, the amount of formazan was measured by measuring the absorbance at 490 nm by an ELISA plate reader (Elisa MAT 2000, DRG Instruments, GmbH, Marburg, Germany).

Immunoblot analysis
For western blotting, firstly, MCF-7 cells were seeded on a six-well plate and allowed to attach for 24 h. Then, the cells were treated with the intended concentrations of VCR, Hst, and their combination and were also incubated for 24 h. After this, the cells were homogenized by centrifugation at 4˚C at 14000 rpm for 14 min with a buffer containing EDTA (1 mM), Na-deoxycholate (0.1%), SDS (0.1%), NP-40 (1%), Tris-HCl (10 mM), protease inhibitors, and sodium orthovanadate (1 mM). The resulting supernatant was drawn and maintained. Protein concentration was measured using the Bradford technique (Bio-Rad Laboratories, Germany). Adequate quantities of protein were injected into a gel with 9% SDS-PAGE, which was then transferred to the nitrocellulose membrane by electrophoresis (Hybond ECL, GE Healthcare Bio-Sciences, USA). After an overnight blockage at 4˚C with 5% skim milk powder in tris-buffer solution and Tween 20 (blocking buffer, TBS-T, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0.1% Tween20), the membrane was impregnated with caspase-3 and NF-κB (p65) (Cell Signaling Technology, Danvers, MA, USA, overnight at 4˚C) at room temperature. After washing with TBS-T (three times, 5 min each time), the stains were incubated for 60 min at room temperature with a secondary peroxidase antibody (1: 15000, GE Healthcare Bio-Sciences Corp. NJ, USA). All antibodies were diluted in the blocking buffer. The antibody-antigen complexes were identified using the ECL system and exposed to the Lumi-Film chemical detection film (Roche Applied Science, Mannheim, Germany). Image j software was employed to estimate the expression intensity. The GAPDH (Cell Signaling Technology, INC. Beverly, MA, USA; 1: 1000) was used as load control.
RNA extraction and real-time PCR

After the 24-hour treatment of the cells with Hst (120 μM), VCR (200 nM), and their combined dose, the RNA was isolated using an RNA extraction kit (AsiaTech Kit, Iran) according to the manufacturer’s instructions. A NanoDrop™ 2000/2000c spectrophotometer was utilized to calculate the quality and concentration of the extracted RNA. Then, the cDNA was synthesized by the Thermo Scientific™ Fermentas kit. After cDNA synthesis, real-time PCR was done using the RealQ Plus 2x Master Mix (AMPLIQON). The primers designed by Oligo 7 software were controlled for their specificity using BLAST on the NCBI site. The formula $2^{-\Delta\Delta CT}$ was used to estimate the percentage of the relative gene expression. The GAPDH gene was used as a housekeeping gene. The primer sequences are shown in Table 1.

Statistical analysis

The data were analyzed using ANOVA. All experiments were done with at least three replications. The western blot band density was measured using Image j software. The results are expressed as mean ± SEM. Statistical significance was defined as $P < 0.05$, $P < 0.01$, and $P < 0.001$.

Results

In silico analyses

Evaluation of the effects of agents on cancer-related cellular pathways by text mining. The results indicated that CT and CP agents had different impacts on cancer treatment. Clustering the results revealed that the effects of the two types of agents on the genes were different, so the two CT agents were placed in one cluster, and the five CP agents were placed in the other cluster (S2 Fig). Among all the studied agents, curcumin and doxorubicin showed the minimum and maximum disadvantages for cancer therapy, respectively. An overview of the results illustrated that CT agents had more negative effects on cancer treatment than CP agents (Fig 1). According to the grouping analysis, Group 2 and Group 1 had the highest number of genes (Fig 2A and 2B), while Group 3 showed the lowest number of genes (Fig 2D).

Protein-protein interaction network analysis. The most important hub genes of each group were identified by examining the PPI network’s six centralities. In Group 1, the genes P53, SRC, RAC1, RPS6, MYC, HSP90AB1, HDAC1, and CDKNA1 (S3 Fig) had the highest score among different centralities. The genes JUN, NF-κB, PCNA, REL, RELA, TRAF, and VCAM1 were the most important hub genes in Group 2 (Fig 3A). The genes YAP1, TRAF2, YAP, TIAM1, and PPARG in Group 3, and genes CLF1, HSPB1, MDM2, SIRT1, and SOD1 (S3 Fig) in Group 4 were the most influential hub genes.

The PPI of Group 2 hub genes indicated that the hub genes of this group were highly correlated with each other and formed a very close unity. The most important pathways associated

Table 1. Primers sequences used in the study.

| Gene      | Forward primer          | Reverse primer          |
|-----------|-------------------------|-------------------------|
| NF-κB     | 5’TGATGATTTTACTAGCAACAAAAG3’ | 5’ ATTATTAAGTATCCCCAGACC 3’ |
| MYC       | 5’CCCACGAGAACAGCAAGAGG3’ | 5’ GACCTACTGATGACCTGACGAGC 3’ |
| GAPDH     | 5’CCACGCAAGAGCACAGAGG3’ | 5’ AGGAGGGGAGTGCTAGTGAG 3’ |
| BCL-2     | 5’TGGGTCATGTGCTGGAGG3’ | 5’ CCGTTCAAGGACTGCTACTCC 3’ |
| P53       | 5’ACCTAAAAAGGAATCTCCACCC3’ | 5’ ACCTTGAGGATAAAAACAGTC 3’ |
| JUN       | 5’CCTGAAAGCTCAGAACTCCGAG3’ | 5’ TGCTGGTTAGCAGATCTTGGC 3’ |

https://doi.org/10.1371/journal.pone.0276458.t001
with these proteins were NF-κB activity, cell adhesion, vascular wound healing, cell cycle, and apoptosis (Fig 3B).

Enrichment analysis. The enrichment analysis of hub genes showed that different groups were involved in many cancer-related processes. Twenty-four terms were significant in the KEGG pathway (KP) analysis, and 120 terms were significant in biological processes (BPs) for Group 1. Most of the KPs were related to cancer, and most of the BPs were related to apoptosis and cell growth (S2 Data). In Group 2, 60 terms were significant in the KPs, and 104 terms were significant in the BPs. The most important processes related to this group are summarized in Tables 2 and 3. The NF-κB signaling pathway was significant in both databases, and other processes were strongly associated with cancer. In Group 3, three terms were significant in the KPs, and 25 were significant in the BPs, among which the processes related to apoptosis were the most common. In Group 4, three terms in the KPs and 54 terms in the BPs were significant, of which the processes related to cellular redox were the most common (S2 Data).

In vitro validation of data

Overview of integrated text mining and PPI for the combination of Hst and VCR. Fig 4 shows the integration of text mining and PPI for the two agents, VCR and Hst, selected for the practical tests. The hub genes obtained from PPI analysis are highlighted in this graph. The hub genes obtained from the PPI network analysis were selected to be examined against the MCF-7 cancer cell line to validate in silico analysis.

The effects of VCR and Hst on MCF-7 cell viability. The MTT assay indicated that Hst could reduce cell viability in a time- and dose-dependent manner in the MCF-7 cell line (Fig 5A). The IC_{50} of Hst was approximately 160 μM for 24 h. VCR at a dose of 400 nM had an IC_{50} (The results are not reported). The combination doses did not have a synergistic effect, and their effect on cell viability was mainly cumulative (Fig 5B). The doses of 120 μM Hst, 200 nM VCR, and their combination were selected for molecular experiments.

Evaluation of hub genes derived from in silico analysis. The combination of Hst and VCR induced apoptosis in the MCF-7 cell line. The combined group was significantly able to induce caspase-3 cleavage. However, the caspase-3 cleavage was much lower in the Hst group.
Fig 2. The effects of agent efficacy on the cancer treatment process through text-mining analysis. A: Group 2 indicated the positive effects of CP and adverse effects of CT on cancer treatment. B: Group 1 indicated that both agents had positive effects on cancer treatment. C: Group 3 indicated that CT had positive effects on cancer treatment, but CP had negative effects on cancer treatment. D: Group 4 indicated that both CT and CP had negative effects on cancer treatment. Blue: Positive effect on cancer treatment. Red: Negative effect on cancer treatment. White: Not available in the literature.

https://doi.org/10.1371/journal.pone.0276458.g002

Fig 3. PPI analysis. A: Hub genes of the top 10 centralities obtained from PPI analysis (Group 2). B: The PPI of the most scored hub genes of the top 10 centralities (Group 2) were obtained through the string database (https://string-db.org/).

https://doi.org/10.1371/journal.pone.0276458.g003
(120 μM) compared to the combined group, and no caspase-3 cleavage was observed at 200 nM VCR (Fig 6A).

The results showed that Hst significantly reduced the expression of NF-κB protein. Treatment of MCF-7 with 200 nM VCR increased the expression of this protein. The combination of Hst and VCR significantly decreased the amount of NF-κB protein compared to the control group (Fig 6B).

The other hub genes derived from in silico analysis were measured by real-time PCR. Hst and VCR significantly increased the expression of TP53. The elevated expression level of this gene was significantly higher in the combined dose compared to the application of each agent individually (Fig 6C). The 120 μM Hst dose and the combined dose reduced the MYC gene

Table 2. Pathways enriched by KEGG for hub genes of Group 2.

| Term                                         | %   | P-Value | Genes                                                                 |
|----------------------------------------------|-----|---------|----------------------------------------------------------------------|
| hsa04668: TNF signaling pathway              | 35.2| 7.5E-13 | IKBKβ, JUN, VCAM1, CHUK, IL1B, CCL2, TRAF1, IKBKG, PTGS2, RELA, NFKB1, PIK3CG |
| hsa05220: Pathways in cancer                 | 50.0| 2.4E-12 | PDGFRB, JUN, CXCL8, CHUK, TRAF1, PTGS2, PIK3CG, RELA, NFKB1, RBX1, IKBKβ, TRAF6, ERBB2, BIRC5, CTNNB1, IKBKG, JAK1 |
| hsa04064: NF-κB signaling pathway            | 32.3| 3.1E-12 | IKBKβ, VCAM1, CXCL8, CHUK, IL1B, TRAF6, TRAF1, IKBKG, PTGS2, RELA, NFKB1, PIK3CG |
| hsa05222: Small cell lung cancer             | 26.4| 3.2E-9  | IKBKβ, CHUK, TRAF6, TRAF1, IKBKG, PTGS2, RELA, NFKB1, PIK3CG         |
| hsa05215: Prostate cancer                    | 26.4| 4.2E-9  | PDGFRB, IKBKβ, CHUK, ERBB2, CTNNB1, IKBKG, RELA, NFKB1, PIK3CG       |
| hsa05212: Pancreatic cancer                  | 23.5| 1.3E-8  | IKBKβ, CHUK, ERBB2, IKBKG, RELA, NFKB1, PIK3CG, JAK1                |
| hsa04010: MAPK signaling pathway             | 29.4| 1.4E-6  | PDGFRB, IKBKβ, JUN, CHUK, IL1B, TRAF6, NFATC3, IKBKG, RELA, NFKB1    |
| hsa04210: Apoptosis                          | 17.6| 8.4E-6  | IKBKβ, CHUK, IKBKG, RELA, NFKB1, PIK3CG                             |
| hsa04014: Ras signaling pathway              | 23.5| 6.2E-5  | PDGFRB, IKBKβ, CHUK, REL, IKBKG, RELA, NFKB1, PIK3CG                |
| hsa04151: PI3K-Akt signaling pathway         | 26.4| 1.3E-4  | PDGFRB, IKBKβ, CHUK, IKBKG, EIF4E, RELA, NFKB1, PIK3CG, JAK1        |

Table 3. Biological possesses enriched by DAVID for hub genes of Group 2.

| Term                                         | %   | P-Value | Genes                                                                 |
|----------------------------------------------|-----|---------|----------------------------------------------------------------------|
| GO:0006954--inflammatory response            | 35.2| 8.3E-11 | IKBKβ, CXCL8, CHUK, IL1B, NFATC3, REL, CCL2, IKBKG, PTGS2, RELA, NFKB1, PIK3CG |
| GO:0051092--positive regulation of NF-κB transcription factor activity | 23.5| 6.0E-9  | IKBKβ, CHUK, IL1B, TRAF6, TRAF1, IKBKG, RELA, NFKB1                 |
| GO:0071356--cellular response to tumor necrosis factor | 17.6| 2.2E-6  | IKBKβ, VCAM1, CXCL8, CHUK, CCL2, RELA                                |
| GO:0051403--stress-activated MAPK cascade     | 11.7| 8.9E-6  | IKBKβ, CHUK, IKBKG, NFKB1                                           |
| GO:0010803--regulation of tumor necrosis factor-mediated signaling pathway | 11.7| 2.7E-5  | IKBKβ, CHUK, TRAF1, IKBKG                                          |
| GO:0006915--apoptotic process                | 20.5| 7.3E-4  | NOTCH2, IL1B, CDK1, BIRC5, TRAF1, IKBKG, NFKB1                      |
| GO:0001525--angiogenesis                     | 14.7| 9.1E-4  | JUN, CXCL8, CCL2, PTGS2, PIK3CG                                    |
| GO:0000082--G1/S transition of mitotic cell cycle | 11.7| 0.001   | LATS1, PCNA, CDK1, EIF4E                                          |
Fig 4. Integrated text mining and PPI for the combined effects of Hst and VCR on cancer-related signaling pathways. The graph was obtained from pathway studio software, and the highlighted colors were added based on PPI analysis. Green highlight: Hub genes of Group 1. Blue highlight: Hub genes of Group 2.

https://doi.org/10.1371/journal.pone.0276458.g004

Fig 5. The cell viability assay. (A) The effects of Hst on MCF-7 cell viability after 24 h and 48 h. (B) The effects of combined doses of Hst and VCR on MCF-7 after 24 h. *: 0.05, **: 0.001 indicates a significant level of control. The level of significance of the combined doses was calculated compared to the corresponding doses in the non-combined state. ###: 0.001 indicates a significant degree of combined groups compared with the VCR group. +++: 0.001 indicates a significant degree of the combined group compared with the related Hst group.

https://doi.org/10.1371/journal.pone.0276458.g005
expression. However, 200 nM VCR did not alter the expression of this gene. There was a significant decrease in the expression of \( JUN \) treated by Hst. The expression of \( JUN \) did not show a significant difference under treatment with VCR, while the combined dose of Hst and VCR significantly reduced the expression of this gene. Treatment with Hst, VCR, and the combination dose, significantly reduced the expression of the \( BCL-2 \) gene in MCF-7 cells (Fig 6C). The results of real-time PCR for \( NF-\kappa B \) were similar to those of western blotting, described above.

**Discussion**

Many studies have been conducted to evaluate the preventive effects of CP agents against cancer [27–29]. Although CPs with low or no side effects are an interesting choice for combination cancer therapy, the benefit of these agents for combination therapy with CT agents is still in a state of ambiguity [12,13,30]. Hence, this investigation evaluated the efficiency of the combination of CT and CP for cancer treatment.

Through clustering the results of text mining, it was revealed that the effects of CT agents were different from the impacts of CP agents on cancer treatment. The results indicated that CT agents, with their many unfavorable influences, complicate the cancer treatment process by developing cancer cell resistance [31–33]. There was at least one positive cluster (CT or CP) in 95% of the data acquired from the grouping of the text-mining results. Group 2 was the largest, indicating that CP agents can retrieve the disadvantages of CT agents in many cases. Whether CP agents, if combined with CT agents, could cover these disadvantages should be validated in practical experiments.

Since targeting all the disadvantages of CT agents to improve their performance is not easy, intelligent therapy targets the most significant ones. The most important hub genes of the four groups were extracted by measuring six important centralities of the PPI network. These hub genes, which are engaged in various cellular processes, were the most effective genes obtained from PPI analysis in the human genome network. Introducing these genes can pave the way for intelligent therapy in combination with cancer therapy. Interestingly, the results of a study by Notarbartolo et al. in 2005 were similar to the findings of the present research in relation to the hub genes in the PPI of Group 2 [34]. In Notarbartolo et al.’s study, curcumin reduced the increased NF-\( \kappa B \) levels of doxorubicin treatment in HA22T/VGH hepatic cancer cells.
Another study showed that curcumin reduced NF-κB (p56) delivery to the nucleus, thereby reducing the enhanced effect of NF-κB by doxorubicin [35].

The enrichment results indicated that the Group 1 and Group 2 hub genes were involved in various processes closely related to cancer and its treatment. As one of the main programmed cell death processes, apoptosis was one of the most important enriched processes for Group 1. Among enriched processes of Group 2, NF-κB activity, angiogenesis, inflammation, apoptosis, and cell cycle were the most important ones, all of which play vital roles in cell fate and resistance to treatment. These findings illustrated that CP agents, in combination with CT agents, can be effective in crucial processes related to cancer treatment.

The hub genes obtained from text mining and PPI of combined Hst and VCR were examined in the MCF-7 cancer cell line to validate the in silico results (Fig 4). The cell viability assay revealed that in most of the doses used, the lethality of VCR combined with Hst was cumulative and no antagonistic or synergistic effect was observed. Although Hst did not have a synergistic effect on cell death, its additive effect could be beneficial for combination therapy with CT agents. It has been reported that CP agents cause a synergistic or additive effect on cancer cell death [36–39].

In silico analysis results were confirmed by western blot and real-time PCR. The NF-κB protein is one of the most important proteins that determines cell fate and is also involved in drug resistance [40,41]. Text-mining results illustrated that the expression level of this gene was increased by CT agents, which could lead to cell growth, proliferation, and treatment resistance [42]. In addition, this gene was nominated as one of the most important hub genes in the PPI analysis. Interestingly, Hst reduced the expression of NF-κB in the combined dose and prevented the effect of VCR on the elevated expression of this protein. This effect may cause cancer cells to be more susceptible to apoptosis and reduce resistance to treatment.

Apoptosis is one of the main therapeutic strategies to fight cancer. Caspase 3 cleavage is known as a fundamental apoptosis marker [43]. Martino et al. (2018) reported that VCR, in combination with other drugs, induced cell death more efficiently [44]. Similarly, the combination of VCR with Satureja khuzestanica extract induced apoptosis in MCF-7 cancer cells [45]. Therefore, it can be concluded that combined doses can synergistically induce apoptosis, which was supported by results of western blotting, indicating proper compatibility of these two agents for apoptosis induction. Chen et al. (2002) demonstrated that reducing NF-κB and BCL-2 expression induced apoptosis in the human clone cell [46]. Thus, this synergistic effect on the induction of apoptosis may be due to the inhibitory effect of Hst on the NF-κB expression. The analysis of the TP53, MYC, BCL-2, and JUN genes performed by real-time PCR also supported the appropriate compatibility of these two agents for cancer therapy which were consistent with the in silico analysis. The TP53 gene, the most important cell guard, showed an increase in expression under the influence of different doses and the combined dose. This increase in expression can be a switch for inducing apoptosis [47]. The BCL-2 and MYC genes, important genes for resistance to apoptosis [48,49], indicated a decrease under various treatments. The JUN, one of the genes stimulated by NF-κB [50], showed a decrease in the group treated with Hst but it did not change significantly in treatment with VCR. Both NF-κB and JUN genes were reduced in the combination group, which could cause a reduction in cell growth and induction of apoptosis.

Although the in vitro results confirmed the in silico results, for a better understanding of molecular mechanisms involved in apoptosis induced by combining drug agents, more comprehensive studies such as whole-cell transcriptome analysis are required. In some studies, the combination of CP and CT effects has not shown satisfactory results against cancer [14,15] when oral and non-targeted administration were used during chemotherapy. Thus, it is suggested that new methods of intelligent drug delivery should be used in addition to targeting...
the hub genes obtained in this study to achieve the effective performance of combination therapy with these two types of agents. For example, a study illustrated that nanoparticles loaded with docetaxel and resveratrol made HER-2-positive breast cancer cells sensitive to docetaxel [51].

Conclusion

In this study, an integrated text mining and PPI analysis approach was used for the first time to investigate the combined effects of therapeutic agents for cancer treatment. The results revealed that CP agents could eliminate many CT disadvantages in many cancer treatment processes. The enrichment analysis of these disadvantages indicated that they were involved in essential and effective processes in cancer treatment. For instance, some of these crucial processes were TNF signaling pathway, the NF-κB signaling pathway, inflammatory response, etc. Some hub genes of this study can be a therapeutic target for intelligent cancer treatment with these agents. It was also illustrated that the effects of VCR in combination with Hst had a good harmony in cancer treatment which could partly validate the results of in silico analysis.

Supporting information

S1 Fig. Graph of human protein-protein interaction network.
(PDF)

S2 Fig. Text-mining clustering based on the impact of each agent on the cancer treatment process.
(PDF)

S3 Fig. Hub-genes of top 10 centralities obtained from PPI analysis.
(PDF)

S1 File. Text-mining results for cancer treatment.
(XLSX)

S1 Data.
(XLSX)

S2 Data. Enrichment analysis for Hub-genes derived from PPI.
(XLSX)

S1 Raw images.
(PDF)

Acknowledgments

We would like to thank the Biology Department of Shahid Bahonar University of Kerman for providing the laboratory for this research. Also, we are grateful to Dr. Esmaeil Ebrahimie for providing access to the pathway studio.

Author Contributions

Conceptualization: Mohammad Rasoul Samandari Bahraseman, Babak Khorsand.
Investigation: Mohammad Rasoul Samandari Bahraseman, Solmaz Sarhadi.
Methodology: Keyvan Esmaeilzadeh-Salestani, Solmaz Sarhadi.
Resources: Mohammad Rasoul Samandari Bahraseman, Nima Hatami.
Software: Mohammad Rasoul Samandari Bahraseman, Babak Khorsand.
Supervision: Babak Khorsand.
Validation: Keyvan Esmaeilzadeh-Salestani, Evelin Loit.
Writing – original draft: Keyvan Esmaeilzadeh-Salestani.
Writing – review & editing: Nima Hatami, Banafsheh Khaleghdoust, Evelin Loit.

References
1. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010; 11: 220–228. https://doi.org/10.1038/nrm2858 PMID: 20177397
2. Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018; 9: 245. https://doi.org/10.3389/fphar.2018.00245 PMID: 29623040
3. Shabani A. A review of Anticancer Properties of Herbal Medicines. J Pharm Care Heal Syst. 2016; 3: 2–5. https://doi.org/10.4172/2376-0419.1000160
4. Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. Int J Mol Sci. 2017; 18: 656. https://doi.org/10.3390/ijms18030656 PMID: 28304343
5. Kwon KH, Barve A, Yu S, Huang MT, Kong ANT. Cancer chemoprevention by phytochemicals: Potential molecular targets, biomarkers and animal models. Acta Pharmacol Sin. 2007; 28: 1409–1421. https://doi.org/10.1111/j.1745-7254.2007.00694.x PMID: 17723174
6. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proceedings. 1976. pp. 1332–1338. PMID: 770206
7. Arumugam A, Razis AFA. Apoptosis as a mechanism of the chemopreventive activity of glucosinolates: A review. Asian Pacific J Cancer Prev. 2018; 19: 1439–1448. https://doi.org/10.22034/JPJCP.2018.19.6.1439 PMID: 29936713
8. Pezzani R, Salehi B, Vitalini S, Inti M, Zuliga FA, Sharifi-Rad J, et al. Synergistic effects of plant derivatives and conventional chemotherapeutic agents: An update on the cancer perspective. Med. 2019; 55: 110. https://doi.org/10.3390/medicina55040110 PMID: 30999703
9. Cao J, Chen Z, Chi J, Sun Y, Sun Y. Recent progress in synergistic chemotherapy and phototherapy by targeted drug delivery systems for cancer treatment. Artif Cells, Nanomedicine Biotechnol. 2018; 46: 817–830. https://doi.org/10.1080/21691401.2018.1436553 PMID: 29405791
10. Rizeq B, Gupta I, Ilesanmi J, AlSafran M, Rahman MDM, Oughtt A. The power of phytochemicals combination in cancer chemoprevention. J Cancer. 2020; 11: 4521–4533. https://doi.org/10.7150/jca.34374 PMID: 32489469
11. Salehi B, Fokou PVT, Yamthe LRT, Tali BT, Adetunji CO, Rahavian A, et al. Phytochemicals in prostate cancer: From bioactive molecules to upcoming therapeutic agents. Nutrients. 2019; 11: 1483. https://doi.org/10.3390/nu11071483 PMID: 31261861
12. Mehta RG, Murillo G, Nalithani R, Peng X. Cancer chemoprevention by natural products: How far have we come? Pharm Res. 2010; 27: 950–961. https://doi.org/10.1007/s11095-010-0085-y PMID: 20238150
13. Zhang Y, Li H, Zhang J, Zhao C, Lu S, Qiao J, et al. The combinatory effects of natural products and chemotherapy drugs and their mechanisms in breast cancer treatment. Phytochem Rev. 2020; 19: 1179–1197. https://doi.org/10.1007/s11101-019-09628-w
14. Wolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, et al. Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment. J Cancer Res Clin Oncol. 2021; 1–13. https://doi.org/10.1007/s00432-021-03675-7 PMID: 34228225
15. Johnson SB, Park HS, Gross CP, Yu JB. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers. Obstet Gynecol Surv. 2019; 74: 217–219. https://doi.org/10.1097/01.ogx.0000554348.70661.56
16. Steinhagen H. The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. By Enrique Ravina. ChemMedChem. John Wiley & Sons; 2011. https://doi.org/10.1002/cmdc.20100321
17. van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH. Vincaependuced peripheral neuropathy in children with cancer: A systematic review. Crit Rev Oncol Hematol. 2017; 114: 114–130. https://doi.org/10.1016/j.critrevonc.2017.04.004 PMID: 28477739
18. Weisfeld-Adams JD, Dutton GN, Murphy DM. Vincristine sulfate as a possible cause of optic neuropathy. Pediatr Blood Cancer. 2007; 48: 238–240. https://doi.org/10.1002/pbc.20638 PMID: 16206187

19. Lobert S. Neurotoxicity in cancer chemotherapy: vinca alkaloids. Crit Care Nurse. 1997; 17: 71–79. https://doi.org/10.4037/ccn1997.17.4.71 PMID: 9325775

20. Kim GD. Hesperetin inhibits vascular formation by suppressing of the PI3K/AKT, ERK, and p38 MAPK signaling pathways. Prev Nutr Food Sci. 2014; 19: 299–306. https://doi.org/10.3746/pnf.2014.19.4.299 PMID: 25580394

21. Aggarwal V, Tuli HS, Thakral F, Singhal P, Aggarwal D, Srivastava S, et al. Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements. Exp Biol Med. 2020; 245: 486–497. https://doi.org/10.1177/1535370220903671 PMID: 32050794

22. Etchevery SB, Ferrer EG, Naso L, Rivadeneira J, Salinas V, Williams PAM. Antioxidant effects of the VO(IV) hesperidin complex and its role in cancer chemoprevention. J Biol Inorg Chem. 2008; 13: 435–447. https://doi.org/10.1007/s00775-007-0332-9 PMID: 18097692

23. Nikitin A, Egorov S, Daraselia N, Mazo I. Pathway studio—the analysis and navigation of molecular networks. Bioinformatics. 2003; 19: 2155–2157. https://doi.org/10.1093/bioinformatics/btg290 PMID: 14594725

24. Khorsand B, Savadi A, Naghibzadeh M. SARS-CoV-2-human protein-protein interaction network. Infor- matics Med unlocked. 2020; 20: 100413. https://doi.org/10.1016/j.imu.2020.100413 PMID: 32838020

25. Khorsand B, Savadi A, Zahir J, Naghibzadeh M. Alpha influenza virus infiltration prediction using virus-human protein-protein interaction network. Math Biosci Eng. 2020; 17: 3109–3129. https://doi.org/10.3934/mbe.2020176 PMID: 32987519

26. Khorsand B, Savadi A, Naghibzadeh M. Comprehensive host-pathogen protein-protein interaction network analysis. BMC Bioinformatics. 2020; 21: 1–22. https://doi.org/10.1186/s12859-020-03706-z PMID: 32912135

27. Umezawa S, Higurashi T, Komiya Y, Arimoto J, Horita N, Kaneko T, et al. Chemoprevention of colorectal cancer: Past, present, and future. Cancer Sci. 2019; 110: 3018–3026. https://doi.org/10.1111/cas.14149 PMID: 31361372

28. Rather RA, Bhagat M. Cancer chemoprevention and piperine: Molecular mechanisms and therapeutic opportunities. Front Cell Dev Biol. 2018; 6: 10. https://doi.org/10.3389/fcell.2018.00010 PMID: 29497610

29. Zhao Y, Hu X, Zuo X, Wang M. Chemopreventive effects of some popular phytochemicals on human colon cancer: a review. Food Funct. 2018; 9: 4548–4568. https://doi.org/10.1039/c8fo00850g PMID: 30118121

30. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006; 66: 3347–3350. https://doi.org/10.1158/0008-5472.CAN-05-4526 PMID: 16585150

31. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest. 2001; 107: 241–246.

32. Smith LM, Wise SC, Hendrickss DT, Sabichi AL, Bos T, Reddy P, et al. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999; 18: 6063–6070. https://doi.org/10.1086/332023 PMID: 10557095

33. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012; 319: 1–7. https://doi.org/10.1016/j.canlet.2012.01.005 PMID: 22261336

34. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D’Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett. 2005; 224: 53–65. https://doi.org/10.1016/j.canlet.2004.10.051 PMID: 15911101

35. Meiyanro E, Putri DDP, Susidarti RA, Munwanti R, Sardijman, Fitriasari A, et al. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pacific J Cancer Prev. 2014; 15: 179–184. https://doi.org/10.7314/APJCP.2014.15.1.179 PMID: 24528023

36. Patra S, Pradhan B, Nayak R, Behera C, Rout L, Jena M, et al. Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics. Seminars in Cancer Biology. Elsevier; 2021. pp. 310–320. https://doi.org/10.1016/j.semcancer.2020.10.010 PMID: 33152486

37. Pal D, Sur S, Roy R, Mandal S, Kumar Panda C. Epigallocatechin gallate in combination with eugenol or amarogentin shows synergistic chemotherapeutic potential in cervical cancer cell line. J Cell Physiol. 2018; 234: 825–836. https://doi.org/10.1002/jcp.26900 PMID: 30078217
38. Molavi O, Narimani F, Asiaee F, Sharifi S, Tarhiz V, Shayanfar A, et al. Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. Pharm Biol. 2017; 55: 729–739. https://doi.org/10.1080/13880209.2016.1270972 PMID: 28027688

39. Xiao Q, Zhu W, Feng W, Lee SS, Leung AW, Shen J, et al. A review of resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy. Front Pharmacol. 2019; 9: 1534. https://doi.org/10.3389/fphar.2018.01534 PMID: 30687096

40. Arora R, Yates C, Gary BD, McClellan S, Tan M, Xi Y, et al. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer. PLoS One. 2014; 9: e98370. https://doi.org/10.1371/journal.pone.0098370 PMID: 24896091

41. Dolcet X, Liobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005; 446: 475–482. https://doi.org/10.1007/s00428-005-1264-9 PMID: 15856292

42. Yu H, Aravindan N, Xu J, Natarajan M. Inter-and intra-cellular mechanism of NF-kB-dependent survival advantage and clonal expansion of radio-resistant cancer cells. Cell Signal. 2017; 31: 105–111. https://doi.org/10.1016/j.cellsig.2017.01.011 PMID: 28069440

43. Kim EK, Kwon KB, Shin BC, Seo EA, Lee YR, Kim JS, et al. Scopelatin induces apoptosis in human promyeloleukemic cells, accompanied by activations of nuclear factor kb and caspase-3. Life Sci. 2005; 77: 824–836. https://doi.org/10.1016/j.lfs.2005.02.003 PMID: 15936354

44. Martino E, Casamassima G, Castiglione S, Cellupica E, Pantalone S, Papagni F, et al. Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead. Bioorganic Med Chem Lett. 2018; 28: 2816–2826. https://doi.org/10.1016/j.bmcl.2018.06.044 PMID: 30122223

45. Esmaeili-Mahani S, Samandari-Bahreman MR, Yaghoobi MM. In-vitro anti-proliferative and pro-apoptotic properties of Satureja khouzestanica on human breast cancer cell line (MCF-7) and its synergistic effects with anticancer drug vincristine. Iran J Pharm Res. 2021; 17: 343–352. https://doi.org/10.22037/ijpr.2018.2184 PMID: 29755565

46. Chen GG, Lee JFY, Wang SH, Chan UPF, Ip PC, Lau WY. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kb in human colon cancer. Life Sci. 2002; 70: 2631–2646. https://doi.org/10.1016/S0024-3205(02)01510-2

47. Asker C, Wiman KG, Selivanova G. p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun. 1999; 265: 1–6. https://doi.org/10.1006/bbrc.1999.1446 PMID: 10548481

48. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008; 3: e3769. https://doi.org/10.1371/journal.pone.0003769 PMID: 19020659

49. Levine B, Sinha SC, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy. 2008; 4: 600–606.

50. Lin A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays. 2003; 25: 17–24. https://doi.org/10.1002/bies.10204 PMID: 12508278

51. Jurczyk M, Kasperek J, Wrześniok D, Beberok A, Jelonek K. Nanoparticles Loaded with Docetaxel and Resveratrol as an Advanced Tool for Cancer Therapy. Biomedicines. 2022; 10: 1187. https://doi.org/10.3390/biomedicines10051187 PMID: 35625921